Information:
Fel:
ID
33360
Beskrivning
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.; ODM derived from: https://clinicaltrials.gov/show/NCT01290718
Länk
https://clinicaltrials.gov/show/NCT01290718
Nyckelord
Versioner (1)
- 2018-12-06 2018-12-06 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
6 december 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT01290718
Eligibility Breast Cancer NCT01290718
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT01290718
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Gender | Age
Item
female patients, 18-65 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
HER2-positive carcinoma of breast | Measurable lesion
Item
histologically confirmed her2-positive breast cancer with measurable lesions (according to recist criteria)
boolean
C1960398 (UMLS CUI [1])
C1513041 (UMLS CUI [2])
C1513041 (UMLS CUI [2])
Neoplasm Metastasis | Status post First line treatment | Recurrent disease Post Neoadjuvant Therapy | Recurrent disease Post Adjuvant therapy | Herceptin | Taxanes
Item
metastatic disease after first-line therapy or recurrent disease after (neo)adjuvant therapy with herceptin and taxanes
boolean
C0027627 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0277556 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C0600558 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4,1])
C0687676 (UMLS CUI [4,2])
C0677850 (UMLS CUI [4,3])
C0338204 (UMLS CUI [5])
C0796419 (UMLS CUI [6])
C0231290 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0277556 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C0600558 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4,1])
C0687676 (UMLS CUI [4,2])
C0677850 (UMLS CUI [4,3])
C0338204 (UMLS CUI [5])
C0796419 (UMLS CUI [6])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
CNS metastases Poorly controlled
Item
cns metastases which are not well controlled
boolean
C0686377 (UMLS CUI [1,1])
C3853134 (UMLS CUI [1,2])
C3853134 (UMLS CUI [1,2])
sorivudine
Item
simultaneous treatment with sorivudine
boolean
C0207628 (UMLS CUI [1])
Cancer Other | Exception Basal cell carcinoma Cured | Exception Carcinoma in situ of uterine cervix Cured
Item
history of another malignancy within the last 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in-situ of the uterine cervix
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1880198 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1880198 (UMLS CUI [3,3])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1880198 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1880198 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])